Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Program
-
Field
-
to include a letter of motivation detailing research interests and expertise and a CV. Previous knowledge of genome stability and CRISPR/Cas9 methodology is required. In addition, you should have experience in
-
The LIT - Leibniz Institute for Immunotherapy (foundation under civil law) (https://lit.eu/ ) formerly RCI – is a biomedical research center focusing on translational immunology in the fields
-
molecular cell biology (using techniques such as cell culture, CRISPR/Cas9 based genome editing, protein expression and interaction analysis, confocal and live cell microscopy), as well as bioinformatics
-
: 27.02.2026 WHEN TO APPLY:27.03-10.04.2026 WEBSITE: http://wiadomosci.sggw.pl/ https://bazaogloszen.nauka.gov.pl/ https://euraxess.ec.europa.eu/jobs KEY WORDS: molecular biology, RNA biology, bioinformatics
-
for setting up experimental systems to study type VI CRISPR-Cas defense mechanisms and analyzing collateral RNA damage using RNA-sequencing. KEY DUTIES: 60 % 1. Conduct research on RNA-targeting type VI CRISPR
-
cutting-edge techniques including CRISPR based techniques to modulate DDR genes of interest, or to introduce double- and single strand breaks at the HTT CAG repeat. We will assess the factors that promote
-
cell culture, CRISPR/Cas9 based genome editing, protein expression and interaction analysis, light microscopy and cancer assays. A solid background in data analysis, bioinformatics and presentation
-
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt | Germany | 2 months ago
cultures (including patient-based material), work with lung organoids and organoid-immune cell co-culture systems, perform CRISPR/Cas9 gene editing, and investigate epithelial homeostasis & stress responses
-
website: https://www.ucd.ie/workatucd/jobs/ Where to apply Website https://www.aplitrak.com/?adid=eWFzZW1pbi5vemRlbWlyLjE5OTYwLjk5MDhAdW5pY2R1Ymxp… Requirements Research FieldEngineeringEducation LevelPhD
-
data. We have developed in vivo single-cell CRISPR technologies to screen for dozens of molecular factors in vivo during developmental and disease. These technologies are a game-changer in the speed